Last mentioned: Mar 23, 2026
NXT 41X Launch
Anticipated commercial launch of Elutia's next-gen drug-eluting biomaterial.
Lead Plaintiff Deadline
Expected deadline for shareholders to petition the court to serve as lead plaintiff in the case.
Bumble 2.0 Launch
Targeted launch of AI-enabled platform experience.
Secondary Notice
Pomerantz reinforces the filing highlights to ensure broad investor awareness.
Follow-up Disclosure
Secondary announcements highlight the filing and the process for shareholders to join the litigation.
Initial Legal Notice
Pomerantz LLP issues the first public call for shareholders to join the class action.
Class Action Announcement
Pomerantz LLP first alerts investors to the class action filing against Boston Scientific.
Codexis CDMO Expansion
Announced three major CDMO agreements with Bachem, Nitto Avecia, and Axolabs.
SEC 8-K Filing
BSX files a Form 8-K under Item 8.01 (Other Events), potentially triggering market reaction.
Earnings Report
Boston Scientific reports Q4 2025 financial results and provides 2026 guidance.
Elutia FDA Milestone
Expected FDA submission for NXT 41X product line.
Elutia Divestiture
Completed $88M sale of bioenvelope business to Boston Scientific.
Pomerantz LLP has initiated a class action lawsuit against Boston Scientific (BSX), alleging potential violations of federal securities laws. The litigation centers on the company's disclosures during a period of significant expansion and product integration, marking a critical legal challenge for the medical device giant.
Pomerantz LLP has issued a formal notice regarding a class action lawsuit against Boston Scientific Corporation (BSX), alleging potential securities fraud. The litigation focuses on whether the medical technology giant made misleading statements regarding its product pipeline or regulatory compliance during the class period.
Q4 2025 earnings for specialized biotech firms reveal a sector-wide shift toward high-margin manufacturing and strategic divestitures. While Codexis capitalizes on its Merck partnership and ECOsynthesis platform, Elutia has cleared its debt through an $88 million divestiture to Boston Scientific.
The Q4 2025 earnings cycle for mid-cap healthcare and life sciences firms reveals a strategic shift toward high-margin AI integration and portfolio streamlining. Companies like Elutia and Codexis are leveraging divestitures and technology transfers to shore up balance sheets, while AI-driven productivity gains are becoming a primary differentiator in clinical and operational workflows.
The Australian government is significantly reducing subsidies for high-cost spinal cord stimulators following reports of severe patient injuries and a lack of clinical efficacy. This regulatory shift targets a multi-million dollar sector of the medical device market, forcing manufacturers to justify the high price tags of chronic pain technologies.